Cancer News and Research

Latest Cancer News and Research

Seven studies on Oncotype DX breast cancer test to be presented at 33rd CTRC-AACR SABCS

Genomic Health, Inc. today announced that the company will present results from seven studies at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2010 at the Henry B. Gonzalez Convention Center.

4 Dec 2010

NCI director ignorant of cancer prevention, says coalition

On October 22, 2010, Senator Chuck Grassley, ranking member of the Senate Finance Committee, wrote to Dr. Harold Varmus, who was appointed director of the National Cancer Institute (NCI) by President Obama three months previously. The Senator raised questions on the amount of "sponsored travel," sometimes a dozen or more trips a year and almost exclusively to international conferences paid for by outside organizations or companies, taken in recent years by "numerous NCI employees, notably senior leadership."

4 Dec 2010

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

US Oncology, Inc., the nation's leading integrated oncology company, announced today that three investigators affiliated with US Oncology Research participated in studies that will be presented orally at the 52nd American Society of Hematology Annual Meeting and Exposition at the Orange County Convention Center in Orlando, Fla. Dec. 4-7. Five other investigators in the US Oncology Research Network participated in a study that will be displayed as a poster during the conference.

4 Dec 2010

Access adds patient experience testimonial video to MuGard website

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has updated its lead product website, www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.

4 Dec 2010

Personal environment influences effects of genes and risk of disease

Personalized medicine centers on being able to predict the risk of disease or response to a drug based on a person's genetic makeup. But a study by scientists at Washington University School of Medicine in St. Louis suggests that, for most common diseases, genes alone only tell part of the story.

4 Dec 2010

MD Anderson honors CBS correspondent Bob Schieffer

A Conversation With a Living Legend® in Dallas, benefiting The University of Texas MD Anderson Cancer Center, showcases CBS chief Washington correspondent Bob Schieffer as its 21st annual honoree in an interview with NBC News special correspondent Tom Brokaw, 11:30 a.m. to 1:30 p.m. Dec. 13 in the Chantilly Ballroom of the Hilton Anatole, 2201 Stemmons Freeway.

4 Dec 2010

Wide-scale study of flu vaccine's effectiveness in European children needed

A wide-scale study of the effectiveness of flu vaccine in children is needed in Europe to fully assess the benefits, not only in keeping the kids from getting sick, but limiting the spread of flu to adults.

4 Dec 2010

Companies, media organizations join Georgia Prostate Cancer Coalition to launch pledge campaign

Prostate cancer is a serious health concern in Georgia. According to the American Cancer Society, the state of Georgia ranks 11th in number of estimated deaths per capita from the disease. In an effort to raise awareness about prostate cancer and ensure more men commit to be informed and screened, several companies and media organizations have joined the Georgia Prostate Cancer Coalition in launching a pledge campaign.

4 Dec 2010

Decrease in physician reimbursement leads to decline in AST usage for prostate cancer

The use of androgen suppression therapy (AST) in prostate cancer for low-risk cases declined following a decrease in physician reimbursement, according to a study published online TK in The Journal of the National Cancer Institute. However, the indicated use of AST for metastatic disease in the palliative setting did not decline in the same period.

4 Dec 2010

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Pfizer Inc. announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients. These regulatory submissions are planned for 2011.

4 Dec 2010

New web-based CME program to improve cancer care in rural areas

Nearly a quarter of Americans live in rural areas, which consistently report higher cancer mortality rates than urban and suburban areas. Among the complex causes for this disparity is that only 10 percent of physicians practice in rural areas and almost 4 out of 10 rural residents live at least an hour from an urban area. Finding the time, transportation, and financial resources for travel to urban academic medical centers, the standard bearers for quality cancer care, often proves difficult.

4 Dec 2010

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

Onconova Therapeutics announces its late-stage anticancer agent, Estybon- (ON 01910.Na), will be featured in three presentations at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 4-7, 2010.

4 Dec 2010

Clarient extends pending offer, files amendment to Solicitation/Recommendation Statement

Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.

4 Dec 2010

URMC's Cone Beam CT scanner studies presented at RSNA 2010

While questions persist about the best ways to detect breast cancer early, a CT imaging system developed at the University of Rochester Medical Center and first unveiled five years ago is in a better position today to enter the fray -- at least in a supporting role to conventional mammography.

4 Dec 2010

Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting

Ligand Pharmaceuticals Incorporated today announced that multiple clinical studies of dinaciclib (SCH 727965) will be presented by Merck at the upcoming 52nd American Society of Hematology Annual Meeting being held in Orlando, Florida at the Orange County Convention Center, December 4-7, 2010.

4 Dec 2010

MDS Foundation: Significant advances made in understanding, treating MDS, AML

The Myelodysplastic Syndromes Foundation today said significant advances are being made in understanding and treating MDS and a related condition, AML (acute myeloid leukemia). Key studies being presented this week include data on new markers and genetic mutations to predict susceptibility to MDS and response to treatment.

4 Dec 2010

New standard treatment for early stage breast cancer

Spanish Oncology has established a new standard treatment for Breast Cancer at early stages thanks to the results of the study 9805/Target 0 funded by Spanish Breast Cancer Research Group and sponsored by Sanofi Aventis.

4 Dec 2010

Mitoxantrone increases survival for children with relapsed ALL, trial results show

A new treatment increases survival to almost 70 per cent for children whose acute lymphoblastic leukaemia returns, according to the results of a trial published online in the Lancet today (Saturday).

4 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

BRI enters 3-year partnership with Roche to develop human immunology programs

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.

4 Dec 2010